UNITED THERAPEUTICS Corp cotiza a 549.16 USD y tiene una capitalización bursátil de $23.6B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized…
| Periodo | 2026-10 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $7.27 | $5.82 | $7.70 |
| Estimado | $6.21 | $6.86 | $6.86 | $6.76 |
| Sorpresa | — | +6.0% | -15.2% | +13.9% |
| Métrica | UTHR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 87.9% | 57.0% | +30.9% |
| Operating Margin | 46.9% | -38.6% | +85.5% |
| Net Margin | 41.9% | -33.6% | +75.5% |
| FCF Margin | 32.7% | -13.9% | +46.6% |
| ROE | 18.8% | -40.4% | +59.2% |
| ROA | 16.9% | -32.0% | +49.0% |
| Current Ratio | 6.60 | 2.84 | +3.76 |
| Debt / Equity | — | 0.28 | — |